Matrix Metalloproteinase 9 in Prostate Cancer and Benign Prostatic Hyperplasia
Author Information
Author(s): F.C. Hamdy, E.J. Fadlon, D. Cottam, J. Lawry, W. Thurrell, P.B. Silcocks, J.B. Anderson, J.L. Williams, R.C. Rees
Primary Institution: University of Sheffield Medical School
Hypothesis
The study investigates the expression of matrix metalloproteinase 9 (MMP-9) in prostate cancer and benign prostatic hyperplasia (BPH) to determine its potential role in predicting metastatic disease.
Conclusion
MMP-9 expression is significantly higher in malignant prostatic tissue compared to benign tissue, suggesting its potential as a marker for aggressive prostate cancer.
Supporting Evidence
- 64% of patients with skeletal metastases showed 92 kDa MMP-9 activity.
- 73% of aneuploid tumors expressed 92 kDa MMP-9 compared to 20% of diploid tumors.
- 80% of BPH samples expressed a 97 kDa gelatinase, while only 23% of carcinoma patients did.
Takeaway
This study found that a specific protein, MMP-9, is more common in prostate cancer than in non-cancerous prostate tissue, which might help doctors understand how aggressive the cancer is.
Methodology
The study used zymography and Western blotting to analyze MMP-9 expression in tissue samples from patients with prostate cancer and BPH.
Potential Biases
Potential bias may arise from the selection of tissue samples and the inability to isolate cancer cells from surrounding stroma.
Limitations
The study's findings may not fully represent in vivo behavior due to the in vitro nature of the gelatinase activity detection.
Participant Demographics
The study included 41 men aged 46 to 87 years, with 26 having prostate cancer and 15 having BPH.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website